Plaintiff conducted reasonable inquiry before filing suit for infringement of therapeutic method patent, even though plaintiff did not conduct chemical analysis of accused product, and subsequently abandoned action upon learning that defendant’s product contained no more than .00005 percent of composition claimed as principal active ingredient of invention.